Document is current
Any future updates will be listed below
-
Authors
Vermeulen, Lynn https://orcid.org/0000-0002-3903-8466
Depuydt, Christophe E.
Weckx, Petra
Bechter, Oliver
Van Damme, Philip
Thal, Dietmar R.
Claeys, Kristl G.
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Universitaire Ziekenhuizen Leuven, KU Leuven (C14-17-107)
CSL Behring (Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders)
- License Information
-
More Information
Article History
Received: 4 September 2019
Accepted: 15 January 2020
First Online: 29 January 2020
Compliance with ethical standards
:
: Lynn Vermeulen: no conflict of interest; Christophe E. Depuydt: no conflict of interest; Petra Weckx: no conflict of interest; Oliver Bechter: advisory board honoraria from Novartis, MSD, BMS, Sanofi, Merck; travel grant form MSD; Philip Van Damme: no conflict of interest; Dietmar R. Thal: Consultant honorary from GE Healthcare (UK), and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium); Kristl G. Claeys: advisory board honoraria and research grant from Alnylam, Biogen, CSL Behring, Sanofi-Genzyme; travel reimbursement from Sanofi-Genzyme.
: This study received approval from the Ethics Committee Research UZ/ KU Leuven.
